BioMarin Pharmaceutical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMRN research report →
Companywww.biomarin.com
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
- CEO
- Alexander Hardy
- IPO
- 1999
- Employees
- 3,040
- HQ
- San Rafael, CA, US
Price Chart
Valuation
- Market Cap
- $9.64B
- P/E
- 35.74
- P/S
- 2.97
- P/B
- 1.55
- EV/EBITDA
- 18.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.93%
- Op Margin
- 13.55%
- Net Margin
- 8.29%
- ROE
- 4.41%
- ROIC
- 3.92%
Growth & Income
- Revenue
- $3.22B · 12.87%
- Net Income
- $348.90M · -18.26%
- EPS
- $1.82 · -19.11%
- Op Income
- $533.48M
- FCF YoY
- 52.49%
Performance & Tape
- 52W High
- $66.28
- 52W Low
- $49.26
- 50D MA
- $54.90
- 200D MA
- $56.03
- Beta
- 0.23
- Avg Volume
- 2.15M
Get TickerSpark's AI analysis on BMRN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 26 | Friberg Gregory R | sell | 3,281 |
| Mar 18, 26 | Davis George Eric | other | 1,273 |
| Mar 17, 26 | Guyer Charles Greg | other | 1,693 |
| Mar 17, 26 | Mueller Brian | other | 2,117 |
| Mar 17, 26 | Hardy Alexander | other | 4,252 |
| Mar 16, 26 | Hubbard Cristin | other | 15,410 |
| Mar 17, 26 | Hubbard Cristin | other | 1,245 |
| Mar 16, 26 | Hubbard Cristin | other | 36,680 |
| Mar 16, 26 | Friberg Gregory R | other | 19,150 |
| Mar 17, 26 | Friberg Gregory R | other | 1,629 |
Our BMRN Coverage
We haven't published any research on BMRN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BMRN Report →